Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant/adjuvant tiragolumab plus atezolizumab with or without platinum chemotherapy in resectable locally advanced NSCLC
NL-OMON51422Phase 2Active, not recruiting
- Sponsor
- Roche
- Start
- Apr 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of tiragolumab and atezolizumab in non-small cell lung cancer (NSCLC) (2 cohorts), sponsored by Roche. Started Apr 2022; status: active, not recruiting.
02
Drugs
tiragolumabatezolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON51422.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51422.